The Nk Cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Nk Cell Therapy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Nk Cell Therapy Market.
Some of the key takeaways from the Nk Cell Therapy Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Nk Cell Therapy treatment therapies with a considerable amount of success over the years.
-
Nk Cell Therapy companies working in the treatment market are ONK Therapeutics, Catamaran Bio, Chimeric Therapeutics, Gamida-Cell, Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd., Innate Pharma, and others, are developing therapies for the Nk Cell Therapy treatment
-
Emerging Nk Cell Therapy therapies in the different phases of clinical trials are- ONKT102, CAT-179, CHM 0201, GDA-201, AB 101, DF1001, AFM13, Evencaleucel, GTA002, BVAC-C, SMT-NK, Monalizumab, and others are expected to have a significant impact on the Nk Cell Therapy market in the coming years.
-
In October 2024, ImmunityBio, Inc. (NASDAQ: IBRX), a leader in immunotherapy, announced the initiation of its first clinical trial evaluating CD-19-targeted CAR-NK cell therapy for non-Hodgkin’s lymphoma (NHL). The QUILT 106 trial involves testing high-affinity natural killer (t-haNK) cells initially as a standalone treatment and subsequently, upon confirming safety, in combination with rituximab, a standard therapy for NHL. This Phase 1 open-label study, targeting patients with CD19+ and CD20+ relapsed/refractory B-cell NHL, aims to enroll up to 10 participants and is being conducted at sites in Johannesburg, Pretoria, and Bloemfontein, South Africa.
-
In April 2024, Artiva Biotherapeutics, Inc., a clinical-stage company dedicated to advancing off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced the dosing of the first patient in its Phase 1 trial of AlloNK® (AB-101). This trial evaluates AlloNK in combination with monoclonal antibodies for treating lupus nephritis (LN) (ClinicalTrials.gov Identifier: NCT06265220). AlloNK, a cryopreserved, non-genetically modified allogeneic NK cell therapy candidate, is designed to enhance the efficacy of B-cell-targeting monoclonal antibodies to promote B-cell depletion.
Nk Cell Therapy Overview
Natural Killer (NK) Cell Therapy is an innovative immunotherapy that uses NK cells, a type of immune cell, to target and destroy cancerous or infected cells. NK cells are part of the body's innate immune system and are known for their ability to recognize and kill abnormal cells without prior sensitization. In NK cell therapy, these cells are often modified or expanded in the laboratory to enhance their effectiveness and are then delivered to patients to treat conditions such as cancer, autoimmune diseases, and viral infections. This approach is gaining traction for its potential in precision medicine and immune modulation.
Get a Free Sample PDF Report to know more about Nk Cell Therapy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight
Emerging Nk Cell Therapy Drugs Under Different Phases of Clinical Development Include:
-
ONKT102: ONK Therapeutics
-
CAT-179: Catamaran Bio
-
CHM 0201: Chimeric Therapeutics
-
GDA-201: Gamida-Cell
-
AB 101: Artiva Biotherapeutics
-
DF1001: Dragonfly therapeutics
-
AFM13: Affimed
-
Evencaleucel: XNK Therapeutics
-
GTA002: Glycostem
-
BVAC-C: CELLID
-
SMT-NK: SMT bio Co., Ltd.
-
Monalizumab: Innate Pharma
Nk Cell Therapy Route of Administration
Nk Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Infusion
-
Intradermal
-
Intramuscular
-
Intranasal
-
Intravaginal
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical.
-
Molecule Type
Nk Cell Therapy Molecule Type
Nk Cell Therapy Products have been categorized under various Molecule types, such as
-
Vaccines
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Product Type
Nk Cell Therapy Pipeline Therapeutics Assessment
-
Nk Cell Therapy Assessment by Product Type
-
Nk Cell Therapy By Stage and Product Type
-
Nk Cell Therapy Assessment by Route of Administration
-
Nk Cell Therapy By Stage and Route of Administration
-
Nk Cell Therapy Assessment by Molecule Type
-
Nk Cell Therapy by Stage and Molecule Type
DelveInsight's Nk Cell Therapy Report covers around 185+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Nk Cell Therapy product details are provided in the report. Download the Nk Cell Therapy pipeline report to learn more about the emerging Nk Cell Therapy therapies
Some of the key companies in the Nk Cell Therapy Therapeutics Market include:
Key companies developing therapies for Nk Cell Therapy are - Therapeutics, Dragonfly Therapeutics, Dynavax, Exacis Biotherapeutics,, Fate Therapeutics, Feldan Therapeutics, Five Prime Therapeutics, Glycostem, Glycostem Therapeutics (IPD Therapeutic), Green Cross Corporation, GT Biopharma, HiberCell, iCell Gene Therapeutics, ImmunityBio, Innate Pharma, Kiadis Pharma, Kuur Therapeutics (Formerly Cell Medica), Multimmune GmbH, Abivax, Acepodia, Affimed Therapeutics AG, Agenus, Allife Medical Science and Technology, Artiva Biotherapeutics, Asclepius Technology Company Group, Bellicum Pharmaceuticals, Bright Path Biotherapeutics, Bristol-Myers Squibb, Cantargia, CARsgen therapeutics, Celgene Corporation/Celularity, Cellid Company, Celularity, Celyad Oncology, Chongqing Sidemu Biotechnology, CiMass, CureTech, CytoImmune Therapeutics, CytoVac, Cytovia Therapeutics, Dragonfly Therapeutics, Dynavax, Exacis Biotherapeutics,, Fate Therapeutics, Feldan Therapeutics, Five Prime Therapeutics, Glycostem, Glycostem Therapeutics (IPD Therapeutic), Green Cross Corporation, GT Biopharma, HiberCell, iCell Gene Therapeutics, ImmunityBio, Innate Pharma, Kiadis Pharma, Kuur Therapeutics (Formerly Cell Medica), Multimmune GmbH, NantKwest, Nektar Therapeutics, NKMax, ONK Therapeutics, Orgenesis, PersonGen BioTherapeutics (Suzhou), Surface Oncology, Synimmune, Vycellix, XNK Therapeutics, and others.
Nk Cell Therapy Pipeline Analysis:
The Nk Cell Therapy pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Nk Cell Therapy with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nk Cell Therapy Treatment.
-
Nk Cell Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Nk Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nk Cell Therapy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Nk Cell Therapy drugs and therapies
Nk Cell Therapy Pipeline Market Drivers
-
Increase in clinical and pre-clinical research with positive results, increase in collaborations and acquisitions between companies, increasing interest towards NK Cell Therapies among biotech and pharma companies, enhanced efficacy of NK Cells are some of the important factors that are fueling the Nk Cell Therapy Market.
Nk Cell Therapy Pipeline Market Barriers
-
However, short life span, cumbersome preparation method of CAR NK cells, difficulties with NK cells and other factors are creating obstacles in the Nk Cell Therapy Market growth.
Scope of Nk Cell Therapy Pipeline Drug Insight
-
Coverage: Global
-
Key Nk Cell Therapy Companies: ONK Therapeutics, Catamaran Bio, Chimeric Therapeutics, Gamida-Cell, Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd., Innate Pharma, and others
-
Key Nk Cell Therapy Therapies: ONKT102, CAT-179, CHM 0201, GDA-201, AB 101, DF1001, AFM13, Evencaleucel, GTA002, BVAC-C, SMT-NK, Monalizumab, and others
-
Nk Cell Therapy Therapeutic Assessment: Nk Cell Therapy current marketed and Nk Cell Therapy emerging therapies
-
Nk Cell Therapy Market Dynamics: Nk Cell Therapy market drivers and Nk Cell Therapy market barriers
Request for Sample PDF Report for Nk Cell Therapy Pipeline Assessment and clinical trials
Table of Contents
1. Nk Cell Therapy Report Introduction
2. Nk Cell Therapy Executive Summary
3. Nk Cell Therapy Overview
4. Nk Cell Therapy- Analytical Perspective In-depth Commercial Assessment
5. Nk Cell Therapy Pipeline Therapeutics
6. Nk Cell Therapy Late Stage Products (Phase II/III)
7. Nk Cell Therapy Mid Stage Products (Phase II)
8. Nk Cell Therapy Early Stage Products (Phase I)
9. Nk Cell Therapy Preclinical Stage Products
10. Nk Cell Therapy Therapeutics Assessment
11. Nk Cell Therapy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Nk Cell Therapy Key Companies
14. Nk Cell Therapy Key Products
15. Nk Cell Therapy Unmet Needs
16 . Nk Cell Therapy Market Drivers and Barriers
17. Nk Cell Therapy Future Perspectives and Conclusion
18. Nk Cell Therapy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
